Based on Phase IIa trial data where 85% of patients had resolution of chronic fatigue over 20% with placebo, the company will now offer its cord blood cell therapy outside of the...
After stepping back from stem cell therapies last year, Novo is passing the torch on diabetes cell therapies to Aspect Biosystems, who will continue to commercialize the tech.
Dr. Joshua Hare's Longeveron is working on MSC therapy for seniors with "inflammaging", securing a new method-of-use patent with the USPTO.
The therapy is getting close to conditional approval for our feline friends.
The Australian biotech company is preparing for trials and commercialization of its stem cell therapy platform for Crohn's disease, StemSmart.
NeuroScientific brings Dr. Cole onboard as it advances stem cell research and prepares for clinical trials.
The trial will investigate whether umbilical cord stem cell therapy can calm the autoimmune condition.
Sana Biotechnology reported six-month clinical data demonstrating successful survival and function of transplanted islet cells without immunosuppressive medication.
The company has concluded dosing in its largest pediatric diabetes trial, evaluating ProTrans therapy's safety and insulin-preserving potential
Vertex recently presented encouraging Phase 1/2 results for zimislecel, a stem cell-derived therapy showing sustained insulin production in type 1 diabetes patients.
